JAMA Oncol 2020 Apr 16
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Related Questions
Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?
3
2 Answers
Mednet Member
Medical Oncology · Mayo Clinic
Yes, but only for highly selected patients. Might consider discussing retreatment with PRRT (R-PRRT) in those who: 1. Derived good response (or prolonged stable disease) with prior PRRT and,2. Don't have better options available (for example, would not do R-PRRT before CapTem, afinitor, sutent in pN...
For a metastatic neuroendocrine tumor patient who has experienced prolonged progression free survival, how would you approach surgical debulking?
1 Answers
Mednet Member
Medical Oncology · Mayo Clinic
This is a complicated answer (especially for me as a medical oncologist...). The main factors to consider are the tumor grade, tumor behavior, extent and location of metastases, patient's age and performance, and the location of the primary tumor. For a patient with a G1/G2 pancreatic or SB NET with...